Skip to main content
SpringerLink
Log in

Palliative Radiotherapy for Lung Cancer

  • Chapter
  • First Online:
Airway diseases

  • 28 Accesses

Abstract

Lung cancer (LC) is the second most common cancer expected to be newly diagnosed in 2020 and the most leading cause of cancer deaths, in both men and women [1]. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all LC patients, and 10–15% have small-cell lung cancer (SCLC). At diagnosis, approximately 60% of the LCs are diagnosed at stage III or IV [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

    Article  PubMed  Google Scholar 

  2. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL. Siegel RL (2019) cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69(5):363–85. https://doi.org/10.3322/caac.21565.

    Article  PubMed  Google Scholar 

  3. Rodrigues G, Macbeth F, Burmeister B, Kelly KL, Bezjak A, Langer C, Hahn C, Movsas B. Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer. 2012;13(1):1–5. https://doi.org/10.1016/j.cllc.2011.04.004.

    Article  PubMed  Google Scholar 

  4. Macbeth FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, Machin D, Stephens RJ, Bailey AJ. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party Clin Oncol (R Coll Radiol). 1996;8(3):167–75. https://doi.org/10.1016/s0936-6555(96)80041-0.

    Article  CAS  PubMed  Google Scholar 

  5. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006;85(1):37–42. https://doi.org/10.1097/01.md.0000198474.99876.f0.

    Article  PubMed  Google Scholar 

  6. Straka C, Ying J, Kong FM, Willey CD, Kaminski J, Kim DW. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. Springerplus. 2016;5:229. https://doi.org/10.1186/s40064-016-1900-7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002;14(5):338–51. https://doi.org/10.1053/clon.2002.0095.

    Article  CAS  PubMed  Google Scholar 

  8. Ostler PJ, Clarke DP, Watkinson AF, Gaze MN. Superior vena cava obstruction: a modern management strategy. Clin Oncol (R Coll Radiol). 1997;9(2):83–9. https://doi.org/10.1016/s0936-6555(05)80445-5.

    Article  CAS  PubMed  Google Scholar 

  9. Chan RH, Dar AR, Yu E, Stitt LW, Whiston F, Truong P, Vincent MD, Kocha WI. Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1997;38(3):513–20. https://doi.org/10.1016/s0360-3016(97)00094-1.

    Article  CAS  PubMed  Google Scholar 

  10. Egelmeers A, Goor C, van Meerbeeck J, van den Weyngaert D, Scalliet P. Palliative effectiveness of radiation therapy in the treatment of superior vena cava syndrome. Bull Cancer Radiother. 1996;83(3):153–7. https://doi.org/10.1016/0924-4212(96)81747-6.

    Article  CAS  PubMed  Google Scholar 

  11. Maddox AM, Valdivieso M, Lukeman J, Smith TL, Barkley HE, Samuels ML, Bodey GP. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clin Parameters Surv Cancer. 1983;52(11):2165–72. https://doi.org/10.1002/1097-0142(19831201)52:11<2165::aid-cncr2820521132>3.0.co;2-z.

    Article  CAS  Google Scholar 

  12. Sculier JP, Evans WK, Feld R, DeBoer G, Payne DG, Shepherd FA, Pringle JF, Yeoh JL, Quirt IC, Curtis JE, et al. Superior vena caval obstruction syndrome in small cell lung cancer. Cancer. 1986;57(4):847–51. https://doi.org/10.1002/1097-0142(19860215)57:4<847::aid-cncr2820570427>3.0.co;2-h.

    Article  CAS  PubMed  Google Scholar 

  13. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3(8):811–4. https://doi.org/10.1097/JTO.0b013e3181804791.

    Article  PubMed  Google Scholar 

  14. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987;13(4):531–9. https://doi.org/10.1016/0360-3016(87)90068-x.

    Article  CAS  PubMed  Google Scholar 

  15. Davenport D, Ferree C, Blake D, Raben M. Radiation therapy in the treatment of superior vena caval obstruction. Cancer. 1978;42(6):2600–3. https://doi.org/10.1002/1097-0142(197812)42:6<2600::aid-cncr2820420614>3.0.co;2-2.

    Article  CAS  PubMed  Google Scholar 

  16. Gollins SW, Burt PA, Barber PV, Stout R. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol. 1994;33(1):31–40. https://doi.org/10.1016/0167-8140(94)90083-3.

    Article  CAS  PubMed  Google Scholar 

  17. Taulelle M, Chauvet B, Vincent P, Felix-Faure C, Buciarelli B, Garcia R, Brewer Y, Reboul F. High dose rate endobronchial brachytherapy: results and complications in 189 patients. Eur Respir J. 1998;11(1):162–8. https://doi.org/10.1183/09031936.98.11010162.

    Article  CAS  PubMed  Google Scholar 

  18. Lee JW, Lee JH, Kim HK, Shim BY, An HJ, Kim SH. The efficacy of external beam radiotherapy for airway obstruction in lung cancer patients. Cancer Res Treat. 2015;47(2):189–96. https://doi.org/10.4143/crt.2013.261.

    Article  CAS  PubMed  Google Scholar 

  19. Medical Research Council Lung Cancer Working Party. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer. 1992;65(6):934–41. https://doi.org/10.1038/bjc.1992.196.

    Article  Google Scholar 

  20. Lupattelli M, Maranzano E, Bellavita R, Chionne F, Darwish S, Piro F, Latini P. Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study. Am J Clin Oncol. 2000;23(1):89–93. https://doi.org/10.1097/00000421-200002000-00024.

    Article  CAS  PubMed  Google Scholar 

  21. Nihei K, Ishikura S, Kawashima M, Ogino T, Ito Y, Ikeda H. Short-course palliative radiotherapy for airway stenosis in non-small cell lung cancer. Int J Clin Oncol. 2002;7(5):284–8. https://doi.org/10.1007/s101470200041.

    Article  PubMed  Google Scholar 

  22. Chang LF, Horvath J, Peyton W, Ling SS. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys. 1994;28(3):589–96. https://doi.org/10.1016/0360-3016(94)90183-x.

    Article  CAS  PubMed  Google Scholar 

  23. Gollins SW, Ryder WD, Burt PA, Barber PV, Stout R. Massive haemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus. Radiother Oncol. 1996;39(2):105–16. https://doi.org/10.1016/0167-8140(96)01731-8.

    Article  CAS  PubMed  Google Scholar 

  24. Roach M 3rd, Leidholdt EM Jr, Tatera BS, Joseph J. Endobronchial radiation therapy (EBRT) in the management of lung cancer. Int J Radiat Oncol Biol Phys. 1990;18(6):1449–54. https://doi.org/10.1016/0360-3016(90)90321-a.

    Article  PubMed  Google Scholar 

  25. Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys. 1993;25(4):579–87. https://doi.org/10.1016/0360-3016(93)90002-d.

    Article  CAS  PubMed  Google Scholar 

  26. Speiser BL, Spratling L. Radiation bronchitis and stenosis secondary to high dose rate endobronchial irradiation. Int J Radiat Oncol Biol Phys. 1993;25(4):589–97. https://doi.org/10.1016/0360-3016(93)90003-e.

    Article  CAS  PubMed  Google Scholar 

  27. Harms W, Schraube P, Becker H, Latz D, Herth F, Fritz P, Wannenmacher M. Effect and toxicity of endoluminal high-dose-rate (HDR) brachytherapy in centrally located tumors of the upper respiratory tract. Strahlenther Onkol. 2000;176(2):60–6. https://doi.org/10.1007/pl00002329.

    Article  CAS  PubMed  Google Scholar 

  28. Hennequin C, Bleichner O, Tredaniel J, Quero L, Sergent G, Zalcman G, Maylin C. Long-term results of endobronchial brachytherapy: a curative treatment? Int J Radiat Oncol Biol Phys. 2007;67(2):425–30. https://doi.org/10.1016/j.ijrobp.2006.08.068.

    Article  PubMed  Google Scholar 

  29. Stout R, Barber P, Burt P, Hopwood P, Swindell R, Hodgetts J, Lomax L. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol. 2000;56(3):323–7. https://doi.org/10.1016/s0167-8140(00)00252-8.

    Article  CAS  PubMed  Google Scholar 

  30. Chute CG, Greenberg ER, Baron J, Korson R, Baker J, Yates J. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer. 1985;56(8):2107–11. https://doi.org/10.1002/1097-0142(19851015)56:8<2107::aid-cncr2820560837>3.0.co;2-t.

    Article  CAS  PubMed  Google Scholar 

  31. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440–4. https://doi.org/10.1378/chest.112.2.440.

    Article  CAS  PubMed  Google Scholar 

  32. Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev. 2016;11:CD008711. https://doi.org/10.1002/14651858.CD008711.pub3.

    Article  PubMed  Google Scholar 

  33. Gaito S, Hughes C, Woolf D, Radhakrishna G. Radiotherapy in the control of bleeding from primary and secondary lung tumours. Br J Hosp Med (Lond). 2019;80(4):211–5. https://doi.org/10.12968/hmed.2019.80.4.211.

    Article  PubMed  Google Scholar 

  34. Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008;26(24):4001–11. https://doi.org/10.1200/JCO.2007.15.3312.

    Article  PubMed  Google Scholar 

  35. Stevens R, Macbeth F, Toy E, Coles B, Lester JF. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015;1:CD002143. https://doi.org/10.1002/14651858.CD002143.pub4.

    Article  PubMed  Google Scholar 

  36. Rees GJ, Devrell CE, Barley VL, Newman HF. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol). 1997;9(2):90–5. https://doi.org/10.1016/s0936-6555(05)80446-7.

    Article  CAS  PubMed  Google Scholar 

  37. Nestle U, Nieder C, Walter K, Abel U, Ukena D, Sybrecht GW, Schnabel K. A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys. 2000;48(1):95–103. https://doi.org/10.1016/s0360-3016(00)00607-6.

    Article  CAS  PubMed  Google Scholar 

  38. Erridge SC, Gaze MN, Price A, Kelly CG, Kerr GR, Cull A, MacDougall RH, Howard GC, Cowie VJ, Gregor A. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005;17(1):61–7. https://doi.org/10.1016/j.clon.2004.09.008.

    Article  CAS  PubMed  Google Scholar 

  39. Inoperable non-small-cell lung cancer (NSCLC). A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its lung cancer working party. Br J Cancer. 1991;63(2):265–70. https://doi.org/10.1038/bjc.1991.62.

    Article  Google Scholar 

  40. Simpson JR, Francis ME, Perez-Tamayo R, Marks RD, Rao DV. Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys. 1985;11(4):751–8. https://doi.org/10.1016/0360-3016(85)90307-4.

    Article  CAS  PubMed  Google Scholar 

  41. Sundstrom S, Bremnes R, Aasebo U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol. 2004;22(5):801–10. https://doi.org/10.1200/JCO.2004.06.123.

    Article  PubMed  Google Scholar 

  42. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Mlynski E, Pliszka A, Kubrak J, Lewandowska A, Malachowski K, Wierzchowski M, Matecka-Nowak M, Jassem J. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). Br J Cancer. 2005;92(6):1038–45. https://doi.org/10.1038/sj.bjc.6602477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Anacak Y, Mogulkoc N, Ozkok S, Goksel T, Haydaroglu A, Bayindir U. High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer. Lung Cancer. 2001;34(2):253–9. https://doi.org/10.1016/s0169-5002(01)00249-5.

    Article  CAS  PubMed  Google Scholar 

  44. Ozkok S, Karakoyun-Celik O, Goksel T, Mogulkoc N, Yalman D, Gok G, Bolukbasi Y. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer. 2008;62(3):326–33. https://doi.org/10.1016/j.lungcan.2008.03.018.

    Article  PubMed  Google Scholar 

  45. Zaric B, Perin B, Jovelic A, Lalic N, Secen N, Kopitovic I, Antonic M. Clinical risk factors for early complications after high-dose-rate endobronchial brachytherapy in the palliative treatment of lung cancer. Clin Lung Cancer. 2010;11(3):182–6. https://doi.org/10.3816/CLC.2010.n.023.

    Article  PubMed  Google Scholar 

  46. Reveiz L, Rueda JR, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2012;12:CD004284. https://doi.org/10.1002/14651858.CD004284.pub3.

    Article  PubMed  Google Scholar 

  47. Rodrigues G, Videtic GM, Sur R, Bezjak A, Bradley J, Hahn CA, Langer C, Miller KL, Moeller BJ, Rosenzweig K, Movsas B. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1(2):60–71. https://doi.org/10.1016/j.prro.2011.01.005.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Stewart A, Parashar B, Patel M, O’Farrell D, Biagioli M, Devlin P, Mutyala S. American brachytherapy society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy. 2016;15(1):1–11. https://doi.org/10.1016/j.brachy.2015.09.006.

    Article  CAS  PubMed  Google Scholar 

  49. Scottish Intercollegiate Guidelines Network (2014) Management of patients with lung cancer: A national clinical guideline. https://www.sign.ac.uk/assets/sign137.pdf. Accessed 25 Mar 2019.

  50. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, Supportive Care Guidelines Group of Cancer Care Ontario’s Program in Evidence-Based C. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2005;31(4):256–73. https://doi.org/10.1016/j.ctrv.2005.04.007.

    Article  PubMed  Google Scholar 

  51. Stella GM, Corino A, Berzero G, Kolling S, Filippi AR, Benvenuti S. Brain metastases from lung cancer: is MET an actionable target? Cancers (Basel). 2019;11(3) https://doi.org/10.3390/cancers11030271.

  52. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–304. https://doi.org/10.1200/JCO.2005.04.6185.

    Article  CAS  PubMed  Google Scholar 

  53. Porter AT, David M. Palliative care for bone, spinal cord, brain and liver metastases. In: Gunderson LL, Tepper JE, editors. Clinical radiation oncology. Philadelphia: Elsevier; 2007. p. 437–55.

    Google Scholar 

  54. Narayana A, Liebel SA. Primary and metastatic brain tumors. In: Liebel SA, Phillips TL, editors. Textbook of radiation oncology. Philadelphia: Elsevier; 2004. p. 463–95.

    Google Scholar 

  55. Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013;106(3):370–4. https://doi.org/10.1016/j.radonc.2013.01.015.

    Article  PubMed  Google Scholar 

  56. Hendriks LE, Troost EG, Steward A, Bootsma GP, De Jaeger K, van den Borne BE, Dingemans AM. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: impact of a new Dutch guideline on brain metastases. Acta Oncol. 2014;53(7):945–51. https://doi.org/10.3109/0284186X.2014.906746.

    Article  CAS  PubMed  Google Scholar 

  57. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D, Holt T, Morgan S, Lee C, Waite K, Bayman N, Pugh C, Sydes B, Stephens R, Parmar MK, Langley RE. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14. https://doi.org/10.1016/S0140-6736(16)30825-X.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Jeene PM, de Vries KC, van Nes JGH, Kwakman JJM, Wester G, Rozema T, Braam PM, Zindler JD, Koper P, Nuyttens JJ, Vos-Westerman HA, Schmeets I, Niel C, Hutschemaekers S, van der Linden YM, Verhoeff JJC, Stalpers LJA. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018;57(5):637–43. https://doi.org/10.1080/0284186X.2017.1418534.

    Article  PubMed  Google Scholar 

  59. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51. https://doi.org/10.1016/s0360-3016(96)00619-0.

    Article  CAS  PubMed  Google Scholar 

  60. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4. https://doi.org/10.1016/j.ijrobp.2007.06.074.

    Article  PubMed  Google Scholar 

  61. Sperduto CM, Watanabe Y, Mullan J, Hood T, Dyste G, Watts C, Bender GP, Sperduto P. A validation study of a new prognostic index for patients with brain metastases: the graded prognostic assessment. J Neurosurg. 2008;109(Suppl):87–9. https://doi.org/10.3171/JNS/2008/109/12/S14.

    Article  PubMed  Google Scholar 

  62. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61. https://doi.org/10.1016/j.ijrobp.2009.08.025.

    Article  PubMed  Google Scholar 

  63. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–25. https://doi.org/10.1200/JCO.2011.38.0527.

    Article  PubMed  Google Scholar 

  64. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol. 2017;3(6):827–31. https://doi.org/10.1001/jamaoncol.2016.3834.

    Article  PubMed  Google Scholar 

  65. Nieder C, Hintz M, Oehlke O, Bilger A, Grosu AL. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). Radiat Oncol. 2017;12(1):107. https://doi.org/10.1186/s13014-017-0844-6.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Zindler JD, Slotman BJ, Lagerwaard FJ. Patterns of distant brain recurrences after radiosurgery alone for newly diagnosed brain metastases: implications for salvage therapy. Radiother Oncol. 2014;112(2):212–6. https://doi.org/10.1016/j.radonc.2014.07.007.

    Article  PubMed  Google Scholar 

  67. Rodrigues G, Warner A, Zindler J, Slotman B, Lagerwaard F. A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. Radiother Oncol. 2014;111(1):52–8. https://doi.org/10.1016/j.radonc.2013.11.015.

    Article  PubMed  Google Scholar 

  68. Ayala-Peacock DN, Peiffer AM, Lucas JT, Isom S, Kuremsky JG, Urbanic JJ, Bourland JD, Laxton AW, Tatter SB, Shaw EG, Chan MD. A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro-Oncology. 2014;16(9):1283–8. https://doi.org/10.1093/neuonc/nou018.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Ayala-Peacock DN, Attia A, Braunstein SE, Ahluwalia MS, Hepel J, Chung C, Contessa J, McTyre E, Peiffer AM, Lucas JT Jr, Isom S, Pajewski NM, Kotecha R, Stavas MJ, Page BR, Kleinberg L, Shen C, Taylor RB, Onyeuku NE, Hyde AT, Gorovets D, Chao ST, Corso C, Ruiz J, Watabe K, Tatter SB, Zadeh G, Chiang VLS, Fiveash JB, Chan MD. Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. J Neuro-Oncol. 2017;135(2):403–11. https://doi.org/10.1007/s11060-017-2588-4.

    Article  Google Scholar 

  70. Aoyama H, Tago M, Shirato H, Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015;1(4):457–64. https://doi.org/10.1001/jamaoncol.2015.1145.

    Article  PubMed  Google Scholar 

  71. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–41. https://doi.org/10.1200/JCO.2010.30.1655.

    Article  PubMed  Google Scholar 

  72. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91. https://doi.org/10.1001/jama.295.21.2483.

    Article  CAS  PubMed  Google Scholar 

  73. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44. https://doi.org/10.1016/S1470-2045(09)70263-3.

    Article  PubMed  Google Scholar 

  74. Leung A, Lien K, Zeng L, Nguyen J, Caissie A, Culleton S, Holden L, Chow E. The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2011;11(6):693–700. https://doi.org/10.1586/erp.11.66.

    Article  PubMed  Google Scholar 

  75. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Menard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9. https://doi.org/10.1001/jama.2016.9839.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6. https://doi.org/10.1200/JCO.2014.57.2909.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72. https://doi.org/10.1016/S0140-6736(04)16250-8.

    Article  PubMed  Google Scholar 

  78. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, Nagano O, Kenai H, Moriki A, Suzuki S, Kida Y, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Kikuchi Y, Shibasaki T, Goto T, Takanashi M, Mori Y, Takakura K, Saeki N, Kunieda E, Aoyama H, Momoshima S, Tsuchiya K. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387–95. https://doi.org/10.1016/S1470-2045(14)70061-0.

    Article  PubMed  Google Scholar 

  79. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76. https://doi.org/10.1053/ctrv.2000.0210.

    Article  CAS  PubMed  Google Scholar 

  80. Fairchild A. Palliative radiotherapy for bone metastases from lung cancer: evidence-based medicine? World J Clin Oncol. 2014;5(5):845–57. https://doi.org/10.5306/wjco.v5.i5.845.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Gutt R, Dawson G, Cheuk AV, Fosmire H, Moghanaki D, Kelly M, Jolly S. Palliative radiotherapy for the Management of Metastatic Cancer: bone metastases, spinal cord compression, and brain metastases. Fed Pract. 2015;32(Suppl 4):12S–6S.

    PubMed  PubMed Central  Google Scholar 

  82. Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O’Reilly MS, Lewis VO. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5(6):872–8. https://doi.org/10.1001/jamaoncol.2019.0192.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E, Wiggenraad RG, Hoogenhout J, Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo I, Rutten E. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch bone metastasis study. Radiother Oncol. 1999;52(2):101–9. https://doi.org/10.1016/s0167-8140(99)00110-3.

    Article  CAS  PubMed  Google Scholar 

  84. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005;97(11):798–804. https://doi.org/10.1093/jnci/dji139.

    Article  PubMed  Google Scholar 

  85. Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H, DeAngelis C, Chow E. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review. Radiother Oncol. 2017;122(3):323–31. https://doi.org/10.1016/j.radonc.2016.12.031.

    Article  PubMed  Google Scholar 

  86. Chow R, Hoskin P, Schild SE, Raman S, Im J, Zhang D, Chan S, Chiu N, Chiu L, Lam H, Chow E, Lock M. Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis. Radiother Oncol. 2019;141:56–61. https://doi.org/10.1016/j.radonc.2019.06.037.

    Article  PubMed  Google Scholar 

  87. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4–12. https://doi.org/10.1016/j.prro.2016.08.001.

    Article  PubMed  Google Scholar 

  88. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24(2):112–24. https://doi.org/10.1016/j.clon.2011.11.004.

    Article  CAS  PubMed  Google Scholar 

  89. Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014;15(2):164–71. https://doi.org/10.1016/S1470-2045(13)70556-4.

    Article  PubMed  Google Scholar 

  90. Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(15):1463–72. https://doi.org/10.1016/S1470-2045(15)00199-0.

    Article  CAS  PubMed  Google Scholar 

  91. Lei M, Liu Y, Liu S, Wang L, Zhou S, Zhou J. Individual strategy for lung cancer patients with metastatic spinal cord compression. Eur J Surg Oncol. 2016;42(5):728–34. https://doi.org/10.1016/j.ejso.2016.01.018.

    Article  CAS  PubMed  Google Scholar 

  92. Ribas ES, Schiff D. Spinal cord compression. Curr Treat Options Neurol. 2012;14(4):391–401. https://doi.org/10.1007/s11940-012-0176-7.

    Article  PubMed  Google Scholar 

  93. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–8. https://doi.org/10.1016/S0140-6736(05)66954-1.

    Article  PubMed  Google Scholar 

  94. Rades D, Huttenlocher S, Dunst J, Bajrovic A, Karstens JH, Rudat V, Schild SE. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol. 2010;28(22):3597–604. https://doi.org/10.1200/JCO.2010.28.5635.

    Article  PubMed  Google Scholar 

  95. Boussios S, Cooke D, Hayward C, Kanellos FS, Tsiouris AK, Chatziantoniou AA, Zakynthinakis-Kyriakou N, Karathanasi A. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38(9):4987–97. https://doi.org/10.21873/anticanres.12817.

    Article  PubMed  Google Scholar 

  96. Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabilic R, Karstens JH, Alberti W, Dunst J, Schild SE. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24(21):3388–93. https://doi.org/10.1200/JCO.2005.05.0542.

    Article  PubMed  Google Scholar 

  97. Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, Bajrovic A, Rudat V, Schwarz R, Hulshof MC, Poortmans P, Schild SE. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005;23(15):3366–75. https://doi.org/10.1200/JCO.2005.04.754.

    Article  PubMed  Google Scholar 

  98. Ropper AE, Ropper AH. Acute spinal cord compression. N Engl J Med. 2017;376(14):1358–69. https://doi.org/10.1056/NEJMra1516539.

    Article  PubMed  Google Scholar 

  99. Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, McKinna F, Foran B, Madhavan K, MacGregor C, Bates A, O’Rourke N, Lester JF, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas SS, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with Spinal Canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322(21):2084–94. https://doi.org/10.1001/jama.2019.17913.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Cho YJ, Cho YM, Kim SH, Shin KH, Jung ST, Kim HS. Clinical analysis of patients with skeletal metastasis of lung cancer. BMC Cancer. 2019;19(1):303. https://doi.org/10.1186/s12885-019-5534-3.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Oliveira M, Marques BC, Matos RA, Fontenelle C, Mello FCQ, Paschoal MEM. Pathological fractures due to bone metastases from lung cancer: risk factors and survival. Acta Ortop Bras. 2018;26(6):388–93. https://doi.org/10.1590/1413-785220182606201669.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Van der Linden YM, Dijkstra PD, Kroon HM, Lok JJ, Noordijk EM, Leer JW, Marijnen CA. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br. 2004;86(4):566–73.

    Article  PubMed  Google Scholar 

  103. Townsend PW, Smalley SR, Cozad SC, Rosenthal HG, Hassanein RE. Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. Int J Radiat Oncol Biol Phys. 1995;31(1):43–9. https://doi.org/10.1016/0360-3016(94)E0310-G.

    Article  CAS  PubMed  Google Scholar 

  104. Wolanczyk MJ, Fakhrian K, Adamietz IA. Radiotherapy, bisphosphonates and surgical stabilization of complete or impending pathologic fractures in patients with metastatic bone disease. J Cancer. 2016;7(1):121–4. https://doi.org/10.7150/jca.13377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, İstinye University Faculty of Medicine, İstanbul, Turkey

    Görkem Türkkan

  2. Department of Radiation Oncology, Liv Hospital Ulus, İstanbul, Turkey

    Görkem Türkkan

  3. Faculty of Medicine, Department of Radiation Oncology, Eskisehir Osmangazi University, Eskisehir, Turkey

    Alaattin Özen

  4. GROW School for Oncology and Developmental Biology, Department of Radiation Oncology (MAASTRO Clinic), Maastricht University Medical Centre, Maastricht, The Netherlands

    Dirk de Ruysscher

Authors
  1. Görkem Türkkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alaattin Özen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dirk de Ruysscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Otorhinolaryngology, Eskişehir Osmangazi University, Eskisehir, Türkiye

    Cemal Cingi

  2. Department of Pulmonology, Celal Bayar University, Manisa, Türkiye

    Arzu Yorgancıoğlu

  3. Department of Otorhinolaryngology, Kırıkkale University, Kırıkkale, Türkiye

    Nuray Bayar Muluk

  4. Federal University of Bahia School of Medicine and ProAR Foundation, Salvador - Bahia, Brazil

    Alvaro A. Cruz

Section Editor information

  1. Department of Chest Disease, Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey

    Muzaffer Metintaş MD

  2. Department of Chest Disease, Eskisehir Osmangazi University, Eskisehir, Turkey

    Guntulu Ak

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Türkkan, G., Özen, A., de Ruysscher, D. (2023). Palliative Radiotherapy for Lung Cancer. In: Cingi, C., Yorgancıoğlu, A., Bayar Muluk, N., Cruz, A.A. (eds) Airway diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-22483-6_74-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-22483-6_74-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-22482-9

  • Online ISBN: 978-3-031-22483-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation